July 9, 2020
Eisai said on July 8 that it has submitted a new drug application in Japan for its EZH2 inhibitor tazemetostat for the treatment of EZH2 gene mutation-positive follicular lymphoma. Tazemetostat, a first-in-class, oral EZH2 inhibitor originated by US biotech Epizyme,...read more